A5037002724- SARS-CoV-2 and COVID-19 Research
- Herpesvirus Infections and Treatments
- Viral gastroenteritis research and epidemiology
- Vaccine Coverage and Hesitancy
- Allergic Rhinitis and Sensitization
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Odor and Emission Control Technologies
- Animal Disease Management and Epidemiology
- Influenza Virus Research Studies
- COVID-19 epidemiological studies
- Animal Virus Infections Studies
- Animal Behavior and Welfare Studies
- Contact Dermatitis and Allergies
- Pharmacological Effects of Natural Compounds
- Long-Term Effects of COVID-19
- Microbial infections and disease research
- Diphtheria, Corynebacterium, and Tetanus
- Health, Medicine and Society
- Olfactory and Sensory Function Studies
- Cytomegalovirus and herpesvirus research
- Anesthesia and Sedative Agents
- Veterinary Pharmacology and Anesthesia
- Animal Nutrition and Physiology
- Livestock and Poultry Management
Santé Publique France
2022-2024
Institut thématique Santé Publique
2022-2024
BackgroundA rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred France December 2021, while Delta was prevailing since July 2021. We aimed to determine whether risk a severe hospital event following symptomatic infection differs for versus Delta.MethodsWe conducted retrospective cohort study compare events (admission intensive care unit or death) between and cases matched according week virological diagnosis age. The analysis adjusted age, sex,...
This cohort study evaluated the protection against symptomatic Omicron BA.5 infection conferred by Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to mRNA Original monovalent vaccines (Pfizer- BioNTech or Moderna). Individuals of ≥60 years old, who received a booster dose between 03/10/2022 and 06/11/2022, when both were used in France, included matched according type received. The outcome interest was positive SARS-CoV-2 RT-PCR antigenic test associated self-reported symptoms, ≥...
The emergence of SARS-CoV-2 variants calls for continuous monitoring vaccine effectiveness (VE). We estimated the absolute complete 2-dose primary vaccination and booster with COVID-19 mRNA vaccines, duration protection against Delta Omicron BA.1 symptomatic infection severe outcomes. French residents aged ≥50 years, who presented SARS-CoV-2-like symptoms tested between June 6, 2021 February 10, 2022 were included. A test-negative study was conducted to estimate VE infection, using...
In face of evidence rapid waning vaccine effectiveness against Omicron and its sub-lineages, a second booster with mRNA vaccines was recommended for the most vulnerable in France. We used test negative design to estimate relative first protection conferred by previous SARS-CoV-2 infection, symptomatic BA.2 or BA.4/5. included ≥60 years old individuals tested March 21-October 30, 2022. Compared 181-210 days booster, restored 41% [95%CI: 39-42%], 7-30 post-vaccination. This gain lower than one...
Abstract This cohort study aimed to evaluate the protection against symptomatic SARS-CoV-2 infection conferred by Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared mRNA Original (ancestral) monovalent vaccines. Individuals of ≥60 years old who received a booster dose between 03/10/2022 and 06/11/2022, when both vaccines were used in France, included. with (1) (Pfizer- BioNTech or Moderna) (2) matched. The outcome interest was positive RT-PCR antigenic test associated self-reported...
The aim of this study was to conduct a descriptive haemoglobin concentration found on high‐prolificacy sows, the relationship between and body reserves, determine whether anaemia is risk factor for reproductive performance. A cohort 308 sows from seven farms followed last third gestation confirmation following gestation. Haemoglobin assessed at four stages cycle: weeks before farrowing, few days three after farrowing. Backfat thickness (BFT) measured parturition. results were analysed using...
Defining shedding and exposure status for PRRSV is essential in herd stabilisation protocols weaning-age pigs a key subpopulation. Oral fluid (OF) sampling welfare-friendly cost saving promising alternative to blood sampling. The first objective of our study was compare the rate detection PRRSV-1 individual serum sample, OF litter-based collected day before weaning. second evaluate interest pooling samples.The performed on 210-sows, exposed, with confirmed shedding, non-vaccinated against...
Abstract Background A rapid increase in incidence of the SARS-CoV-2 Omicron variant occurred France December 2021, while Delta was prevailing since July 2021. We aimed to determine whether risk a severe hospital event following symptomatic infection differs for versus Delta. Methods conducted retrospective cohort study compare events (admission intensive care unit or death) between and cases matched according week virological diagnosis age. The analysis adjusted age, sex, vaccination status,...
A commercial ELISA test to detect serum anti‐gE antibodies Aujeszky's disease virus was adapted for use with muscle exudates. The samples were taken from the diaphragm of pig carcases at slaughterhouse. Three hundred and eightynine pairs exudate compared determine possibility using in a programme control disease. Taking as reference, individual sensitivity 93‐2 per cent specificity 98‐3 cent. concentration exudates on average 20 times lower than that samples.
Abstract In face of evidence rapid waning vaccine effectiveness against Omicron and its sub-lineages, a second booster with mRNA vaccines was recommended for the most vulnerable in France. We used test negative design to estimate relative first protection conferred by previous SARS-CoV-2 infection, symptomatic BA.2 or BA.4/5. included ≥60 years old individuals tested March 21-October 30, 2022. Compared 181-210 days booster, restored 39% [95%CI: 38% - 41%], 7-30 post-vaccination This gain...
Abstract Since the emergence of Omicron, reinfections with SARS-CoV-2 have been rising. We estimated risk reinfection in widely vaccinated French population, from January to August 2022. At nine weeks post-infection, relative reinfection, primary infection pre-Delta variants being reference group, was at 0.43 [95%CI 0.40-0.47] if attributed Delta, 0.21 0.19-0.24] BA.1 and 0.17 [95% CI 0.15-0.18] BA.2, rapidly waned overtime. After a protection similar against BA.2 or BA.4/5 reinfection.